Merck Bullish On Januvia Prospects Despite Soft First Quarter Sales
This article was originally published in The Pink Sheet Daily
The pharma company sees plenty of potential for its top-selling drug even as its sales came in weak during the first quarter. Meanwhile, Merck welcomes its new head of R&D and the potential for change.
You may also be interested in...
Pfizer and Merck have more than a deal on a diabetes candidate in common as both companies saw foreign exchange and patent expiries hit the bottom line in the first quarter and see emerging markets as key growth drivers this year.
The Big Pharma disappoints investors with a weak first quarter and a failure to come to any decisions about the future structuring of the company. Meanwhile, the company made little progress of note during the quarter.
Two of the world’s largest pharmaceutical companies are teaming up to develop a treatment for type 2 diabetes, but the drug will have plenty of competitors with a better market position by the time it faces regulatory approval.